Retatrutide, Eli Lilly's investigational triple agonist, produced up to 30.3% mean weight reduction at 80 weeks in the Phase 3 TRIUMPH-1 trial, with topline results from TRIUMPH-2 and TRIUMPH-3 following in July 2026. That is roughly eight to twelve percentage points beyond tirzepatide's 17.8–22.5% and double semaglutide's 14.9%.
It is not available and will not be for at least eighteen months. Lilly plans a Biologics License Application in Q1 2027; with a standard ten-to-twelve-month review, approval is realistically late 2027 to early 2028. There is no legal route to it outside clinical trial enrolment, and no mechanism to switch to it from tirzepatide today.
What makes it different mechanically
Semaglutide engages one receptor: GLP-1. Tirzepatide engages two, adding GIP, which is the reason it outperformed semaglutide in the SURMOUNT-5 head-to-head. Retatrutide engages three, adding glucagon receptor agonism — and the glucagon component works differently from the other two. Where GLP-1 and GIP act mainly on appetite and insulin sensitivity, glucagon adds a direct signal for energy expenditure and fat oxidation. It is not simply more appetite suppression; it is a second lever.
That mechanistic difference is why the effect size steps up rather than creeping. Each added receptor has produced a discrete jump, and retatrutide is the first agent to reach late-stage trials targeting all three.
| Agent | Receptors | Status | Peak mean weight loss | Evidence | Availability |
|---|---|---|---|---|---|
| Semaglutide (Wegovy) | GLP-1 | Approved | 13.9–15% | STEP programme | Available now |
| Tirzepatide (Zepbound) | GIP + GLP-1 | Approved | 17.8–22.5% | SURMOUNT-1, SURMOUNT-5 | Available now |
| Orforglipron (Foundayo) | Oral GLP-1 | Approved Apr 2026 | ~11–12% | ATTAIN programme | Available now |
| Retatrutide | GIP + GLP-1 + glucagon | Investigational | 24.2–30.3% | TRIUMPH-1 to 4 | Late 2027 at the earliest |
The TRIUMPH programme, briefly
TRIUMPH is Lilly's registrational Phase 3 programme, begun in 2023, enrolling more than 5,800 participants across four core trials. TRIUMPH-1 is the 80-week weight-management trial in adults with obesity or overweight without diabetes and reported topline in May 2026. TRIUMPH-2 and TRIUMPH-3 reported in July 2026, covering obesity with type 2 diabetes and with established cardiovascular disease; in TRIUMPH-2 the 4, 9 and 12 mg doses produced mean reductions of 12.7%, 19.1% and 20.8% alongside A1c reductions of up to 1.6%.
The weight figures in a diabetes population being lower than in TRIUMPH-1 is the expected pattern across this entire drug class, not a retatrutide-specific finding. Tirzepatide shows the same gap between SURMOUNT and SURPASS populations.
Should you wait for it?
No, and the arithmetic is not close. Approval is realistically eighteen to twenty-four months away, supply constraints are likely in the first months after launch, and a first-year price for a novel branded triple agonist will not undercut anything currently on this site. Meanwhile tirzepatide is available today at $199 a month all-in from the cheapest verified route, with 17.8–22.5% mean reduction behind it in published trials.
Waiting means deferring treatment by roughly two years to gain perhaps eight percentage points, at an unknown price, on a schedule that can slip. Most obesity specialists recommend starting on an approved agent now and reassessing in 2028 — and the withdrawal evidence means anyone who does start should plan to continue rather than pause to wait for something better.
What it will not be
It will not be compounded. Compounded preparations exist for tirzepatide and semaglutide because of a specific regulatory history involving shortage designations; a newly approved agent under patent with controlled supply is a different situation entirely. Anyone offering compounded or "research-grade" retatrutide today is selling an unapproved substance with no clinical oversight, and the research-use disclaimer on those products exists so the seller can say you were told.
It will also not be cheap at launch. Novel branded obesity agents enter at list prices well above $1,000 a month, and the manufacturer self-pay channels that have brought Zepbound to $299–$449 took three years and a government agreement to appear.
What it changes about today's decision
Very little, and that is the useful conclusion. If you are choosing a tirzepatide programme this week, choose on twelve-month cost at your maintenance dose, on whether the programme names its pharmacy, and on whether it can be sustained for years. Retatrutide is a reason to keep your prescriber relationship active and to revisit the question in 2028 — not a reason to delay treatment now.
Retatrutide: 30.3% in Phase 3, and the Case Against Waiting: the shortest useful summary
Tirzepatide is a once-weekly injection titrated from 2.5 mg to a 15 mg ceiling in 2.5 mg steps at intervals of at least four weeks, producing roughly 15 to 21% mean weight reduction across the studied maintenance arms at 72 weeks and about 20% against semaglutide's 14% in the only head-to-head trial. It works while it is taken; the withdrawal evidence shows substantial regain after stopping. Compounded preparations cost from $133 a month and are not FDA-approved; brand product is approved and costs considerably more.
Those five facts decide most questions people arrive with. Everything else on this page is detail underneath them — which is worth reading before you spend $2,388 on a first year, but not worth confusing with the outline.
Retatrutide: 30.3% in Phase 3, and the Case Against Waiting: where to go next
If you have not chosen a program, price your expected maintenance dose with the projector rather than reading advertisements. If you have, check what it charges at 10 mg against the price-by-dose table. If you are struggling with side effects, the side-effect reference covers each one with reported frequencies and the red flags that need a clinician. And if a program has refused to name its pharmacy, the verification walkthrough explains why that single answer outranks any price difference.
People also ask about retatrutide
What is retatrutide?
Retatrutide is covered in full on this page, with the clinical detail drawn from the tirzepatide prescribing information and the published SURMOUNT and SURPASS trial program, and any price figures drawn from our tracked dataset and dated to their last verification.
Does retatrutide apply to compounded tirzepatide as well as Zepbound?
The molecule is the same, so the clinical content applies to both. What differs is regulatory status, dose metering and price: compounded preparations are not FDA-approved, arrive as a multi-dose vial you measure yourself, and cost a fraction of the brand routes.
How much does retatrutide cost per month in 2026?
Compounded tirzepatide runs from $133 per month at the entry dose across the 21 compounded programs we track. At a 10 mg maintenance dose the cheapest tracked route is Oak Longevity at $199 per month, or about $2,388 for a first year on the standard escalation. Brand Zepbound through manufacturer self-pay sits well above that and pharmacy retail well above again. Verified 2026-08-05.
Is retatrutide FDA-approved?
Brand tirzepatide (Zepbound and Mounjaro) is FDA-approved. Compounded tirzepatide is not: FDA does not approve compounded drugs and does not review them for safety, effectiveness or quality before they are marketed. The active molecule is the same; the regulatory review is not.
Sources
- US prescribing information for tirzepatide (Zepbound and Mounjaro), Eli Lilly and Company.
- SURMOUNT-1 — tirzepatide once weekly for the treatment of obesity, NCT04184622.
- SURMOUNT-5 — tirzepatide versus semaglutide in adults with obesity, NCT05822830.
- US Food and Drug Administration, human drug compounding — compounded drugs are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality before marketing.
- Program pricing as recorded in our open dataset, with a verification date on every record.